John Koo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Koo has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Mio Nakamura
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
6 shared publications - Abby Jacobson
Bausch Health Companies Inc Bridgewater New Jersey USA
3 shared publications - April W. Armstrong
University of California, Los Angeles, USA
3 shared publications - Bruce Strober
Yale School of Medicine, New Haven, USA
3 shared publications - Earl L. Goehring
Bausch Health Companies Inc, Bridgewater, USA
3 shared publications - Mark Lebwohl
Icahn School of Medicine at Mount Sinai
3 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Dermsquared in SKIN The Journal of Cutaneous Medicine
- Vol. 10 (5) , 3408-3412
Itch Is Now Made Visible: Advances in fMRI and Its Relevance to Dermatology
Pruritus has long presented a diagnostic paradox in dermatology. Despite being among the most frequent patient complaints, it remains undervalued when unaccompanied by visible pathology. Bias toward visual cues in the field has often resulted in a tendency toward systematic neglect during clinical evaluation, and patients presenting with pruritus of unknown origin are frequently mischaracterized with factitious conditions. However, recent neuroimaging advances are revolutionizing our approach to pruritus by rendering central nervous system (CNS) itch pathways directly observable through functional magnetic resonance imaging (fMRI). Pioneering investigations have captured the neural signatures of centrally-originating pruritus, including socially-triggered, contagious itch and expectation-amplified itch through nocebo mechanisms. These studies reveal distinct brain activation patterns and have mapped core CNS-itch circuitry. Such neuroimaging capabilities hold promise for developing objective itch biomarkers, stratifying treatment candidates, and providing objective visual validation of patient-reported symptoms.
- 8 September 2026
- Published by Dermsquared in SKIN The Journal of Cutaneous Medicine
- Vol. 10 (5) , 3408-3412
Open AccessItch Is Now Made Visible: Advances in fMRI and Its Relevance to Dermatology
Pruritus has long presented a diagnostic paradox in dermatology. Despite being among the most frequent patient complaints, it remains undervalued when unaccompanied by visible pathology. Bias toward visual cues in the field has often resulted in a tendency toward systematic neglect during clinical evaluation, and patients presenting with pruritus of unknown origin are frequently mischaracterized with factitious conditions. However, recent neuroimaging advances are revolutionizing our approach to pruritus by rendering central nervous system (CNS) itch pathways directly observable through functional magnetic resonance imaging (fMRI). Pioneering investigations have captured the neural signatures of centrally-originating pruritus, including socially-triggered, contagious itch and expectation-amplified itch through nocebo mechanisms. These studies reveal distinct brain activation patterns and have mapped core CNS-itch circuitry. Such neuroimaging capabilities hold promise for developing objective itch biomarkers, stratifying treatment candidates, and providing objective visual validation of patient-reported symptoms.
- Open Access
- 16 June 2026
- Published by Springer Nature in CNS Drugs
- Vol. 40 (8) , 1029-1036
Managing Dermatologic Delusional Disorders: A US Psychodermatology Perspective for Clinicians
Dermatological delusional disorders, such as delusional infestation (DI), are a unique type of psychosis in which the patient experiences specific delusions, such as parasites or inorganic materials that come out of their skin. Originally, this type of "encapsulated psychosis" was thought to be unresponsive to antipsychotic agents. However, over the past half a century, several medications with antipsychotic properties have been found to be effective in the treatment of these conditions in the USA, especially pimozide and risperidone. Despite effective treatments, several challenges may arise for clinicians in successfully treating patients with these conditions. These challenges include selecting an efficacious medication and skillfully practicing diplomacy and empathy while guiding patients toward effective management. Navigating interactions with patients with DI and their frequent denial of a psychiatric component to their condition often poses additional challenges to patient-provider rapport and proper and timely management. In the USA, many patients with DI are opposed to trying the conventional approach of psychiatric care and immediate trial of antipsychotic medications. This manuscript represents a single-center psychodermatology perspective on managing dermatologic delusional disorders. This article synthesizes clinical experience from a US clinic and situates that experience within the available evidence. High-quality comparative data are limited. Therefore, this paper highlights pragmatic engagement strategies, pharmacotherapy principles, essential safety monitoring, and research priorities. Experience-based recommendations are clearly labeled as such.
- 16 June 2026
- Published by Springer Nature in CNS Drugs
- Vol. 40 (8) , 1029-1036
Open AccessManaging Dermatologic Delusional Disorders: A US Psychodermatology Perspective for Clinicians
Dermatological delusional disorders, such as delusional infestation (DI), are a unique type of psychosis in which the patient experiences specific delusions, such as parasites or inorganic materials that come out of their skin. Originally, this type of "encapsulated psychosis" was thought to be unresponsive to antipsychotic agents. However, over the past half a century, several medications with antipsychotic properties have been found to be effective in the treatment of these conditions in the USA, especially pimozide and risperidone. Despite effective treatments, several challenges may arise for clinicians in successfully treating patients with these conditions. These challenges include selecting an efficacious medication and skillfully practicing diplomacy and empathy while guiding patients toward effective management. Navigating interactions with patients with DI and their frequent denial of a psychiatric component to their condition often poses additional challenges to patient-provider rapport and proper and timely management. In the USA, many patients with DI are opposed to trying the conventional approach of psychiatric care and immediate trial of antipsychotic medications. This manuscript represents a single-center psychodermatology perspective on managing dermatologic delusional disorders. This article synthesizes clinical experience from a US clinic and situates that experience within the available evidence. High-quality comparative data are limited. Therefore, this paper highlights pragmatic engagement strategies, pharmacotherapy principles, essential safety monitoring, and research priorities. Experience-based recommendations are clearly labeled as such.
- Open Access
- 13 May 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (4) , 803-818
Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium
Genital psoriasis remains underdiagnosed and undertreated despite its substantial impact on quality of life. The sensitive nature of genital involvement contributes to diagnostic delays, patient distress, and treatment challenges. The Genital Psoriasis Wellness Consortium, a multidisciplinary panel of US-based clinicians, previously developed consensus statements on physical diagnosis, patient conversations, quality of life impacts, and treatment. We aimed to build on prior work by providing additional considerations to refine best practices across three areas: physical exam and diagnosis; pediatric and adolescent treatment; and adult and geriatric treatment. The panel used the modified Delphi process and nominal group technique, informed by a systematic literature review, with consensus defined as ≥ 75% agreement on a 7-point Likert scale. The panel emphasized routine genital assessment within comprehensive skin exams and proactive empathetic communication to reduce stigma, with verbal consent and the offer of a chaperone as standard practice. In pediatric care, shared decision making among clinicians, caregivers, and patients fosters adherence. In adults and older patients, treatment decisions should consider comorbidities, polypharmacy, and individual goals; prioritizing therapies with established safety in intertriginous areas and minimizing long-term corticosteroid use. Simple regimens and attention to access barriers were identified as important to support adherence. These considerations aim to enhance diagnosis, optimize treatment, and improve outcomes through personalized empathetic care.
- 13 May 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (4) , 803-818
Open AccessConsiderations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium
Genital psoriasis remains underdiagnosed and undertreated despite its substantial impact on quality of life. The sensitive nature of genital involvement contributes to diagnostic delays, patient distress, and treatment challenges. The Genital Psoriasis Wellness Consortium, a multidisciplinary panel of US-based clinicians, previously developed consensus statements on physical diagnosis, patient conversations, quality of life impacts, and treatment. We aimed to build on prior work by providing additional considerations to refine best practices across three areas: physical exam and diagnosis; pediatric and adolescent treatment; and adult and geriatric treatment. The panel used the modified Delphi process and nominal group technique, informed by a systematic literature review, with consensus defined as ≥ 75% agreement on a 7-point Likert scale. The panel emphasized routine genital assessment within comprehensive skin exams and proactive empathetic communication to reduce stigma, with verbal consent and the offer of a chaperone as standard practice. In pediatric care, shared decision making among clinicians, caregivers, and patients fosters adherence. In adults and older patients, treatment decisions should consider comorbidities, polypharmacy, and individual goals; prioritizing therapies with established safety in intertriginous areas and minimizing long-term corticosteroid use. Simple regimens and attention to access barriers were identified as important to support adherence. These considerations aim to enhance diagnosis, optimize treatment, and improve outcomes through personalized empathetic care.
- Open Access
- 11 May 2026
- Published by Dermsquared in SKIN The Journal of Cutaneous Medicine
- Vol. 10 (3) , 3072-3081
Patient Characteristics and Treatment Approaches in Delusional Infestation Across Two Medical Centers: A Retrospective Study
Background: Delusional Infestation (DI) is a psychiatric disorder marked by persistent, false belief of infestation despite medical evidence to the contrary. Large-scale research on DI is limited, with only one population-based study to date. DI remains poorly understood and difficult to manage. Methods: We conducted a multicenter retrospective chart review of adult outpatients seen in tertiary dermatology clinics at the University of Michigan and University of California, San Francisco between January 2021 and May 2024. Patients were identified using relevant ICD codes, and eligibility was confirmed by manual review for DSM-5 criteria for DI. Key clinical and demographic data were extracted, and relevant risk was calculated using national prevalence data from NAMI and SAMHSA. Results: We identified 155 patients with DI; most were female (79%), non-Hispanic (94%), and white (73%). Mean age of onset was 54 years, with a three-year diagnostic delay. Delusions commonly involved parasites (25%) or bugs/insects (27%). Diagnostic evaluations included skin biopsy (34%) and skin scrapings (15%), with significant variation between centers. Substance use and psychiatric comorbidities were prevalent, with elevated relative risks compared to population data. Treatments most often involved antiparasitic agents, pimozide, or second-generation antipsychotics; pimozide was associated with the highest rate of improvement Conclusions: DI primarily affects middle-aged female and is marked by delayed diagnosis, frequent substance use, and psychiatric comorbidities. Despite varied diagnostic approaches, treatment outcomes remain poor. Multidisciplinary care and standardized protocols are needed to improve management and outcomes.
- 11 May 2026
- Published by Dermsquared in SKIN The Journal of Cutaneous Medicine
- Vol. 10 (3) , 3072-3081
Open AccessPatient Characteristics and Treatment Approaches in Delusional Infestation Across Two Medical Centers: A Retrospective Study
Background: Delusional Infestation (DI) is a psychiatric disorder marked by persistent, false belief of infestation despite medical evidence to the contrary. Large-scale research on DI is limited, with only one population-based study to date. DI remains poorly understood and difficult to manage. Methods: We conducted a multicenter retrospective chart review of adult outpatients seen in tertiary dermatology clinics at the University of Michigan and University of California, San Francisco between January 2021 and May 2024. Patients were identified using relevant ICD codes, and eligibility was confirmed by manual review for DSM-5 criteria for DI. Key clinical and demographic data were extracted, and relevant risk was calculated using national prevalence data from NAMI and SAMHSA. Results: We identified 155 patients with DI; most were female (79%), non-Hispanic (94%), and white (73%). Mean age of onset was 54 years, with a three-year diagnostic delay. Delusions commonly involved parasites (25%) or bugs/insects (27%). Diagnostic evaluations included skin biopsy (34%) and skin scrapings (15%), with significant variation between centers. Substance use and psychiatric comorbidities were prevalent, with elevated relative risks compared to population data. Treatments most often involved antiparasitic agents, pimozide, or second-generation antipsychotics; pimozide was associated with the highest rate of improvement Conclusions: DI primarily affects middle-aged female and is marked by delayed diagnosis, frequent substance use, and psychiatric comorbidities. Despite varied diagnostic approaches, treatment outcomes remain poor. Multidisciplinary care and standardized protocols are needed to improve management and outcomes.
- Open Access
- 29 July 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (10) , 3025-3035
Brodalumab: Seven-Year US Pharmacovigilance Report
Introduction Brodalumab, a human interleukin-17 receptor A antagonist, is approved for treating adults with moderate-to-severe plaque psoriasis who qualify for systemic therapy or phototherapy and have experienced treatment failure or loss of response to other systemic treatments. Although brodalumab is distributed in the USA under a Risk Evaluation and Mitigation Strategy that includes a boxed warning regarding suicidal ideation and behavior, a direct causal relationship has not been established. This report examines pharmacovigilance data collected over 7 years of clinical usage to provide an assessment of the long-term safety characteristics of brodalumab. Methods This report evaluated adverse events (AEs) submitted to Ortho Dermatologics from US healthcare providers and patients during the period spanning August 15, 2017 to August 14, 2024. We calculated crude AE reporting rates per 100 patients using Medical Dictionary for Regulatory Activities (MedDRA) v27.0 Preferred Terms and standardized MedDRA queries. Treatment duration was determined by measuring the time between initial and latest prescription-dispensing authorization dates. Results The study encompassed 5449 US patients, representing approximately 7845 patient-years of exposure across the 7-year reporting period. There were no new adjudicated cases of major adverse cardiovascular events in year 7 (0.24/100 patients for the 7-year reporting period), and serious infection cases occurred at a rate of 2.17/100 patients. Among 64 reported malignancies in 55 patients, 4 were assessed as potentially treatment related. Throughout the 7-year period, no completed suicides were reported, and one suicide attempt occurred in year 3. Conclusion The 7-year pharmacovigilance dataset reinforces the safety profile of brodalumab previously established through clinical trials and earlier pharmacovigilance reports, with no completed suicides and a low fungal infection rate. Graphical Abstract
- 29 July 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (10) , 3025-3035
Open AccessBrodalumab: Seven-Year US Pharmacovigilance Report
Introduction Brodalumab, a human interleukin-17 receptor A antagonist, is approved for treating adults with moderate-to-severe plaque psoriasis who qualify for systemic therapy or phototherapy and have experienced treatment failure or loss of response to other systemic treatments. Although brodalumab is distributed in the USA under a Risk Evaluation and Mitigation Strategy that includes a boxed warning regarding suicidal ideation and behavior, a direct causal relationship has not been established. This report examines pharmacovigilance data collected over 7 years of clinical usage to provide an assessment of the long-term safety characteristics of brodalumab. Methods This report evaluated adverse events (AEs) submitted to Ortho Dermatologics from US healthcare providers and patients during the period spanning August 15, 2017 to August 14, 2024. We calculated crude AE reporting rates per 100 patients using Medical Dictionary for Regulatory Activities (MedDRA) v27.0 Preferred Terms and standardized MedDRA queries. Treatment duration was determined by measuring the time between initial and latest prescription-dispensing authorization dates. Results The study encompassed 5449 US patients, representing approximately 7845 patient-years of exposure across the 7-year reporting period. There were no new adjudicated cases of major adverse cardiovascular events in year 7 (0.24/100 patients for the 7-year reporting period), and serious infection cases occurred at a rate of 2.17/100 patients. Among 64 reported malignancies in 55 patients, 4 were assessed as potentially treatment related. Throughout the 7-year period, no completed suicides were reported, and one suicide attempt occurred in year 3. Conclusion The 7-year pharmacovigilance dataset reinforces the safety profile of brodalumab previously established through clinical trials and earlier pharmacovigilance reports, with no completed suicides and a low fungal infection rate. Graphical Abstract
- Open Access
- 27 March 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (5) , 1079-1092
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
Introduction A 27-week analysis of this phase 3 study demonstrated the interchangeability of the adalimumab biosimilar CT-P17 and reference adalimumab. The current 52-week analysis reports secondary data from the open-label extension period (OLE) of the study. Methods In this randomized, double-blind, active-controlled phase 3 study, adults with moderate-to-severe chronic plaque psoriasis received (via prefilled syringe) 80 mg subcutaneous reference adalimumab on day 1, then 40 mg 1 week later, and every other week (EOW) until week 11. At week 13, patients were randomized (1:1) to continue reference adalimumab (“continuous” group) or undergo repeated switching between CT-P17 and reference adalimumab (“switching” group) until week 25. Thereafter, patients entered an OLE and received 40 mg CT-P17 EOW from week 27 to 49, with an end-of-study visit at week 52. Here we present findings from the OLE. Pharmacokinetics (PK), efficacy (including mean percent improvement from baseline in Psoriasis Area Severity Index [PASI] score), safety, and immunogenicity were evaluated. Post hoc subgroup analyses were also conducted. Results Of 327 patients who initiated the OLE, 152 and 160 patients from the switching group and continuous group, respectively, completed the study. Mean serum concentrations were similar between groups throughout the OLE. Efficacy improvements observed up to week 27 were maintained during the OLE and were comparable between groups. At week 52, overall mean (standard deviation [SD]) improvement from baseline in PASI score was 90.34% (16.59). Safety profiles were similar between groups, and immunogenicity did not increase during the OLE. The mean (SD) percent improvement from baseline in PASI score was slightly lower in patients who were antidrug antibody (ADA)-positive versus those who were ADA-negative (89.57 [17.27] versus 97.29 [4.08]) at week 52. Conclusions PK, efficacy, safety, and immunogenicity findings remained consistent throughout the OLE, regardless of prior treatment, and were generally comparable across timepoints. Trial registration ClinicalTrials.gov: NCT05495568.
- 27 March 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (5) , 1079-1092
Open AccessCT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
Introduction A 27-week analysis of this phase 3 study demonstrated the interchangeability of the adalimumab biosimilar CT-P17 and reference adalimumab. The current 52-week analysis reports secondary data from the open-label extension period (OLE) of the study. Methods In this randomized, double-blind, active-controlled phase 3 study, adults with moderate-to-severe chronic plaque psoriasis received (via prefilled syringe) 80 mg subcutaneous reference adalimumab on day 1, then 40 mg 1 week later, and every other week (EOW) until week 11. At week 13, patients were randomized (1:1) to continue reference adalimumab (“continuous” group) or undergo repeated switching between CT-P17 and reference adalimumab (“switching” group) until week 25. Thereafter, patients entered an OLE and received 40 mg CT-P17 EOW from week 27 to 49, with an end-of-study visit at week 52. Here we present findings from the OLE. Pharmacokinetics (PK), efficacy (including mean percent improvement from baseline in Psoriasis Area Severity Index [PASI] score), safety, and immunogenicity were evaluated. Post hoc subgroup analyses were also conducted. Results Of 327 patients who initiated the OLE, 152 and 160 patients from the switching group and continuous group, respectively, completed the study. Mean serum concentrations were similar between groups throughout the OLE. Efficacy improvements observed up to week 27 were maintained during the OLE and were comparable between groups. At week 52, overall mean (standard deviation [SD]) improvement from baseline in PASI score was 90.34% (16.59). Safety profiles were similar between groups, and immunogenicity did not increase during the OLE. The mean (SD) percent improvement from baseline in PASI score was slightly lower in patients who were antidrug antibody (ADA)-positive versus those who were ADA-negative (89.57 [17.27] versus 97.29 [4.08]) at week 52. Conclusions PK, efficacy, safety, and immunogenicity findings remained consistent throughout the OLE, regardless of prior treatment, and were generally comparable across timepoints. Trial registration ClinicalTrials.gov: NCT05495568.
- Open Access
- 26 November 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (1) , 213-222
Brodalumab: Six-Year US Pharmacovigilance Report
Introduction: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the USA, brodalumab has a boxed warning regarding suicidal ideation and behavior and is only available under a Risk Evaluation and Mitigation Strategy, but no causal association has been established. To assess long-term safety of brodalumab, we summarize pharmacovigilance data from 6 years of real-world clinical practice. Methods: Crude adverse event (AE) reporting rates per 100 patients were calculated for common AEs and AEs of special interest reported to Ortho Dermatologics by US patients and healthcare providers from August 15, 2017 through August 14, 2023. Brodalumab exposure was estimated as time from the first to last prescription-dispensing authorization dates. Adverse events were defined by Medical Dictionary for Regulatory Activities v26.0 Preferred Terms and standardized MedDRA queries. Results: Data were collected from 5138 US patients (estimated exposure of 6900 patient-years). Over 6 years, 13 cases of adjudicated major adverse cardiovascular events were reported (0.25 events/100 patients). The rate of serious infections was 2.20 events/100 patients. Since the 5-year report, there was one new case of Candida infection and a serious fungal infection of the elbow. Among 57 reported malignancies affecting 49 patients, 4 were deemed possibly related to brodalumab. One new case of indeterminate inflammatory bowel disease unrelated to brodalumab was reported. No new suicide attempts were reported in year 6, and there were no completed suicides throughout 6 years. Conclusion: Pharmacovigilance data throughout 6 years are consistent with the safety profile of brodalumab established in clinical trials and previous US pharmacovigilance reports, with no completed suicides and a low fungal infection rate. Graphical
- 26 November 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (1) , 213-222
Open AccessBrodalumab: Six-Year US Pharmacovigilance Report
Introduction: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the USA, brodalumab has a boxed warning regarding suicidal ideation and behavior and is only available under a Risk Evaluation and Mitigation Strategy, but no causal association has been established. To assess long-term safety of brodalumab, we summarize pharmacovigilance data from 6 years of real-world clinical practice. Methods: Crude adverse event (AE) reporting rates per 100 patients were calculated for common AEs and AEs of special interest reported to Ortho Dermatologics by US patients and healthcare providers from August 15, 2017 through August 14, 2023. Brodalumab exposure was estimated as time from the first to last prescription-dispensing authorization dates. Adverse events were defined by Medical Dictionary for Regulatory Activities v26.0 Preferred Terms and standardized MedDRA queries. Results: Data were collected from 5138 US patients (estimated exposure of 6900 patient-years). Over 6 years, 13 cases of adjudicated major adverse cardiovascular events were reported (0.25 events/100 patients). The rate of serious infections was 2.20 events/100 patients. Since the 5-year report, there was one new case of Candida infection and a serious fungal infection of the elbow. Among 57 reported malignancies affecting 49 patients, 4 were deemed possibly related to brodalumab. One new case of indeterminate inflammatory bowel disease unrelated to brodalumab was reported. No new suicide attempts were reported in year 6, and there were no completed suicides throughout 6 years. Conclusion: Pharmacovigilance data throughout 6 years are consistent with the safety profile of brodalumab established in clinical trials and previous US pharmacovigilance reports, with no completed suicides and a low fungal infection rate. Graphical
- Open Access
- 9 May 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (5) , 1349-1357
Brodalumab: 5-Year US Pharmacovigilance Report
Introduction Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Although the US prescribing information for brodalumab includes a boxed warning regarding suicidal ideation and behavior, no causal association has been demonstrated. Here, we summarize 5 years of pharmacovigilance data, from August 15, 2017, through August 14, 2022, reported to Ortho Dermatologics by US patients and healthcare providers. Methods Prevalence of the most common adverse events (AEs) listed in the brodalumab package insert (incidence ≥ 1%) and AEs of special interest are described. Brodalumab exposure was estimated as the time from the first to last prescription-dispensing authorization dates. Data were collected from 4744 patients in the USA, with an estimated exposure of 5815 patient-years. Results Over 5 years, 11 cases of adjudicated major adverse cardiovascular events were reported (0.23 events/100 patients), a rate lower than that experienced by patients in the international Psoriasis Longitudinal Assessment and Registry. There were 106 serious infections. No serious fungal infections were reported. There were 40 confirmed and 2 suspected COVID-19 cases, with no new COVID-19-related deaths. Of 49 reported malignancies among 42 patients, 3 were deemed possibly related to brodalumab. No completed suicides and no new suicidal attempts were reported. Conclusion Five-year pharmacovigilance data are consistent with the established safety profile reported in long-term clinical trials and previous pharmacovigilance reports, with no new safety signals.
- 9 May 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (5) , 1349-1357
Open AccessBrodalumab: 5-Year US Pharmacovigilance Report
Introduction Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Although the US prescribing information for brodalumab includes a boxed warning regarding suicidal ideation and behavior, no causal association has been demonstrated. Here, we summarize 5 years of pharmacovigilance data, from August 15, 2017, through August 14, 2022, reported to Ortho Dermatologics by US patients and healthcare providers. Methods Prevalence of the most common adverse events (AEs) listed in the brodalumab package insert (incidence ≥ 1%) and AEs of special interest are described. Brodalumab exposure was estimated as the time from the first to last prescription-dispensing authorization dates. Data were collected from 4744 patients in the USA, with an estimated exposure of 5815 patient-years. Results Over 5 years, 11 cases of adjudicated major adverse cardiovascular events were reported (0.23 events/100 patients), a rate lower than that experienced by patients in the international Psoriasis Longitudinal Assessment and Registry. There were 106 serious infections. No serious fungal infections were reported. There were 40 confirmed and 2 suspected COVID-19 cases, with no new COVID-19-related deaths. Of 49 reported malignancies among 42 patients, 3 were deemed possibly related to brodalumab. No completed suicides and no new suicidal attempts were reported. Conclusion Five-year pharmacovigilance data are consistent with the established safety profile reported in long-term clinical trials and previous pharmacovigilance reports, with no new safety signals.
- Open Access
- 19 January 2024
- Published by Elsevier in JAAD Case Reports
- Vol. 45, 71-73
Pimozide-induced tardive dyskinesia in the treatment of delusions of infestation
- 19 January 2024
- Published by Elsevier in JAAD Case Reports
- Vol. 45, 71-73
Open AccessPimozide-induced tardive dyskinesia in the treatment of delusions of infestation
- 30 March 2021
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (3) , 1319-1323
Treatment of tardive dyskinesia: a review and update for dermatologists managing delusions of parasitosis
This article introduces to the dermatology provider two medications for the treatment of tardive dyskinesia (TD), which were the first medications approved by the US FDA specifically for the treatment of TD. In addition to describing these two new medications, this article will also provide a focused review of the pathogenesis of TD, as well as non-FDA-approved treatments, which have been tried prior to the advent of these medications. A PubMed search was conducted and articles were reviewed by the senior authors and included if they were relevant for dermatologists regarding etiology, symptoms, risk, and treatment of TD. One of the most widely accepted explanations of TD involves the concept of ‘dopamine receptor hypersensitivity state.’ There are several other less well substantiated proposed pathogenic pathways of TD. The clinical manifestation is characterized by involuntary movements. Prevention includes switching to a 2nd generation agent or using the lowest dose possible for the shortest amount of time. Two new FDA-approved medications for TD are also discussed and reviewed. TD now has FDA-approved medications for treatment. Now, there is even more reason for the dermatologist to have increased confidence when treating delusions of parasitosis (DOP) with antipsychotic agents.
- 30 March 2021
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (3) , 1319-1323
Treatment of tardive dyskinesia: a review and update for dermatologists managing delusions of parasitosis
This article introduces to the dermatology provider two medications for the treatment of tardive dyskinesia (TD), which were the first medications approved by the US FDA specifically for the treatment of TD. In addition to describing these two new medications, this article will also provide a focused review of the pathogenesis of TD, as well as non-FDA-approved treatments, which have been tried prior to the advent of these medications. A PubMed search was conducted and articles were reviewed by the senior authors and included if they were relevant for dermatologists regarding etiology, symptoms, risk, and treatment of TD. One of the most widely accepted explanations of TD involves the concept of ‘dopamine receptor hypersensitivity state.’ There are several other less well substantiated proposed pathogenic pathways of TD. The clinical manifestation is characterized by involuntary movements. Prevention includes switching to a 2nd generation agent or using the lowest dose possible for the shortest amount of time. Two new FDA-approved medications for TD are also discussed and reviewed. TD now has FDA-approved medications for treatment. Now, there is even more reason for the dermatologist to have increased confidence when treating delusions of parasitosis (DOP) with antipsychotic agents.